Amgen Partners for Intracellular Delivery of Proteins
Amgen has formed a research collaboration for intracellular biologics with Elasmogen Ltd, an Aberdeen, Scotland-based biopharmaceutical company, and Feldan Therapeutics, a Quebec City, Canada-based company focused on regenerative medicines using a peptide-based delivery method.
The pact seeks to explore the use of intracellular delivery and binding of biologics to bridge the gap between small molecules and biologics. Biologic antibody therapeutics typically act on extracellular targets but intracellular targets, common in small-molecule drug mechanisms, would enables access to a much greater number of targets, according to information from Elasmogen.
Feldan’s Shuttle technology is a peptide-based delivery method that enables the introduction of foreign proteins into cells. Elasmogen’s soloMER’s are small, naturally occurring binding domains. The technology would be used to develop the delivery system and binding domains to two undisclosed intracellular targets for Amgen.
In 2016, Feldan and Elasmogen established an exclusive partnership for the development of intracellular biologics. Working together, their research teams have demonstrated both intracellular and intranuclear delivery of soloMER binding domains.